Research Effect of invitation letter in language of origin on screening attendance: randomised controlled trial in BreastScreen Norway Solveig Hofvind, Nadia Iqbal, Jonas E Thy, et al BMJ 2023; 382 doi: https://doi.org/10.1136/bmj-2023-075465 (Published 19 September 2023)Cite this as: BMJ 2023;382:e075465 Abstract Objective To explore attendance at organised mammographic screening among immigrant groups that received an invitation letter and informatio...

ORIGINAL RESEARCH|ARTICLES IN PRESS Epidemiology and clinical patterns of Lung Abscesses in ICU: A French multicenter retrospective study Vinca Montmeat, Vincent Bonny, Tomas Urbina, et al Chest Published:August 28, 2023 DOI:https://doi.org/10.1016/j.chest.2023.08.020 Abstract Background Data are scarce regarding epidemiology and management of critically ill patients with lung abscesses. Research question What are the clinical and microbiologica...

ORIGINAL RESEARCH|ARTICLES IN PRESS Oxygen therapy in patients with intermediate-risk acute pulmonary embolism: a randomized trial Deisy Barrios, Diego Durán, Carmen Rodríguez, et al Chest Published:September 15, 2023 DOI:https://doi.org/10.1016/j.chest.2023.09.007 ABSTRACT Background The effect of supplemental oxygen therapy in patients with intermediate-risk pulmonary embolism (PE) who do not have hypoxemia at baseline is uncertain. Research Ques...

ORIGINAL RESEARCH|ARTICLES IN PRESS Comparative effectiveness of first-line and alternative antibiotic regimens in hospitalized patients with non-severe community acquired pneumonia: A multi-centre retrospective cohort study Anthony D. Bai, Siddhartha Srivastava, Benjamin KC. Wong, et al Chest Published:August 10, 2023 DOI:https://doi.org/10.1016/j.chest.2023.08.008 Abstract Background There are several antibiotic regimens to treat community-acquired ...

JOURNAL ARTICLE Burden of Respiratory Viruses in Children Less Than 2 Years Old in a Community-based Longitudinal US Birth Cohort  Zheyi Teoh,  Shannon Conrey,  Monica McNeal,  et al Clinical Infectious Diseases, Volume 77, Issue 6, 15 September 2023, Pages 901–909 https://doi.org/10.1093/cid/ciad289 Abstract Background Respiratory viral infections are a major cause of morbidity and hospitalization in young children. Nevertheless, the population burde...

ORIGINAL RESEARCH|ARTICLES IN PRESS Low- Versus Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Patients: A Multi-Center, Retrospective Observational Cohort Study Tatsuya Nagai, Hiroki Matsui, Haruka Fujioka, et al Chest Open AccessPublished:August 10, 2023 DOI:https://doi.org/10.1016/j.chest.2023.08.009 Abstract Background Trimethoprim-sulfamethoxazole (TMP-SMX) is an e...

Original Investigation  October 24/31, 2023 Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial Yuejin Yang, Xiangdong Li, Guihao Chen, et al JAMA. 2023;330(16):1534-1545. doi:10.1001/jama.2023.19524 Key Points Question  Among patients with acute ST-segment elevation myocardial infarction (STEMI), does the addition of a tradit...

Original Investigation  September 19, 2023 Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis Timothy J. Savage, Matthew P. Kronman, Sushama Kattinakere Sreedhara, et al JAMA. 2023;330(11):1064-1073. doi:10.1001/jama.2023.15503 Key Points Question  For pediatric acute sinusitis, is amoxicillin-clavulanate associated with different rates of treatment failure or adverse e...

Review  October 18, 2023 Defining a High-Quality and Effective Morbidity and Mortality Conference: A Systematic Review Brendin R. Beaulieu-Jones, Spencer Wilson, Daniel S. Howard, et al JAMA Surg. Published online October 18, 2023. doi:10.1001/jamasurg.2023.4672 Key Points Question  What format, design, and other attributes of a morbidity and mortality conference (MMC) appear to best advance its stated objectives related to quali...

CHEST INFECTIONS: ORIGINAL RESEARCH| VOLUME 164, ISSUE 3, P625-636, SEPTEMBER 2023 Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial Dermot A. Linden, Hong Guo-Parke, Michael C. McKelvey, et al Chest 2023; 164: 625-636 Open Access Published:March 31, 2023 DOI:https://doi.org/10.1016/j.chest.2023.03.040 Background Epstein-Barr virus (EBV) frequently is measured at high levels in ...